FY2025 EPS Estimates for HRMY Lowered by Cantor Fitzgerald

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) - Research analysts at Cantor Fitzgerald cut their FY2025 EPS estimates for shares of Harmony Biosciences in a note issued to investors on Thursday, February 20th. Cantor Fitzgerald analyst C. Duncan now anticipates that the company will post earnings of $3.27 per share for the year, down from their prior forecast of $3.49. Cantor Fitzgerald has a "Overweight" rating and a $58.00 price objective on the stock. The consensus estimate for Harmony Biosciences' current full-year earnings is $2.43 per share.

Several other research firms have also issued reports on HRMY. Oppenheimer reissued an "outperform" rating and set a $59.00 target price (up from $56.00) on shares of Harmony Biosciences in a report on Wednesday, October 30th. Deutsche Bank Aktiengesellschaft started coverage on shares of Harmony Biosciences in a report on Tuesday, February 11th. They issued a "buy" rating and a $55.00 target price on the stock. Mizuho cut their price target on shares of Harmony Biosciences from $52.00 to $42.00 and set an "outperform" rating for the company in a report on Thursday, February 20th. Needham & Company LLC reissued a "buy" rating and issued a $50.00 price objective on shares of Harmony Biosciences in a research note on Tuesday. Finally, HC Wainwright restated a "buy" rating and set a $75.00 target price on shares of Harmony Biosciences in a research note on Wednesday, February 19th. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $53.67.

Harmony Biosciences Price Performance

NASDAQ:HRMY traded up $2.83 during trading hours on Friday, reaching $37.01. 1,424,520 shares of the company were exchanged, compared to its average volume of 609,715. The business has a 50 day moving average of $36.59 and a 200 day moving average of $35.81. Harmony Biosciences has a 1-year low of $28.14 and a 1-year high of $41.61. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.24 and a quick ratio of 3.20. The company has a market capitalization of $2.11 billion, a P/E ratio of 17.54, a P/E/G ratio of 0.47 and a beta of 0.80.

Insider Activity at Harmony Biosciences

In related news, insider Jeffrey Dierks sold 1,123 shares of the firm's stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $40.00, for a total value of $44,920.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Sandip Kapadia sold 25,000 shares of the business's stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $40.18, for a total transaction of $1,004,500.00. The disclosure for this sale can be found here. Insiders have sold a total of 72,452 shares of company stock valued at $2,831,679 in the last 90 days. 30.80% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Harmony Biosciences

Hedge funds have recently modified their holdings of the business. GAMMA Investing LLC raised its position in Harmony Biosciences by 92.6% during the 4th quarter. GAMMA Investing LLC now owns 907 shares of the company's stock worth $31,000 after purchasing an additional 436 shares during the last quarter. Mendota Financial Group LLC raised its position in shares of Harmony Biosciences by 24,125.0% during the fourth quarter. Mendota Financial Group LLC now owns 969 shares of the company's stock worth $33,000 after acquiring an additional 965 shares during the last quarter. GF Fund Management CO. LTD. acquired a new position in shares of Harmony Biosciences in the fourth quarter worth approximately $41,000. CWM LLC increased its position in Harmony Biosciences by 111.7% during the 3rd quarter. CWM LLC now owns 1,469 shares of the company's stock valued at $59,000 after purchasing an additional 775 shares during the period. Finally, KBC Group NV raised its holdings in Harmony Biosciences by 79.9% during the 4th quarter. KBC Group NV now owns 1,844 shares of the company's stock worth $63,000 after purchasing an additional 819 shares during the last quarter. Institutional investors and hedge funds own 86.23% of the company's stock.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.